The Synclara Cough System uses mechanical technology to help patients with weak coughs clear their airways and reduce infection risks.
RT’s Three Key Takeaways:
- Mechanical Cough Simulation: The system uses mechanical insufflation-exsufflation technology to simulate a natural cough by rapidly shifting air pressure to loosen and remove mucus from the upper airways.
- Patient-Centric Features: Specialized settings including Patient Synchrony and Positive Airway Pressure on Pause are designed to improve therapy individualization and patient comfort during sessions.
- Versatile Application: The portable, 10-pound device is designed for both pediatric and adult patients and is suitable for use in acute care hospital settings or at home.
Baxter has introduced the Synclara Cough System, a noninvasive therapy designed to simulate a cough and remove secretions for patients with compromised peak cough flow. According to information from the company, the device uses mechanical insufflation-exsufflation (MIE) technology to clear the upper airways, providing an alternative to invasive suctioning.
The system operates by applying positive insufflatory pressure to inflate the airways before rapidly shifting to negative exsufflatory pressure. This process mimics the natural cough response of the body to loosen and evacuate mucus, which helps maintain lung function and reduce the risk of infections, according to a product overview from Baxter.
Key features of the device include Patient Synchrony and Positive Airway Pressure (PAP) on Pause. The PAP on Pause setting allows the system to maintain a positive pressure flow to the patient between cough sessions. The device is programmable via a touchscreen interface, allowing healthcare providers to customize therapy schedules for individual care plans.
The system is intended for pediatric and adult patients experiencing diaphragm or respiratory weakness, often caused by neuromuscular disorders or other respiratory conditions. The device weighs 10 pounds and is portable for use in various settings.
“At Baxter, we set out to make that therapy as effective and comfortable as possible. The Synclara Cough System is the result,” according to the company website.
Baxter provides support through its CARE Connex Program, which includes a team of more than 200 professionals to assist with the therapy experience. Licensed clinical trainers are available to demonstrate the system and program cough schedules for patients.
The device is currently available for use in both home care and acute care settings, with specific warranty options provided for each environment. According to Baxter, the system is designed to provide “specialized patient training, therapy optimization and support.”
